Pharmaceutical Italian drug developer Newron Pharmaceuticals (SIX: NWRN) says that it has signed a strategic collaboration and licence option with privately-held Zambon, also Based in Italy, for its lead compound safinamide, rights to which were returned to Newron last year by Merck Serono and effective April 17 this year (The Pharma Letter October 24, 2011). 9 April 2012